diabetic macular oedema

5 observations about corticosteroids for DME treatmentFindings from studies investigating intravitreal corticosteroids for treatment of diabetic macular edema (DME) provide information about their efficacy and safety, including some understanding of how they compare with anti-VEGF therapy.
NICE recommends dexamethasone adalimumab for uveitisThe UK’s National Institute for Health and Care Excellence (NICE) has given preliminary approval to dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) and adalimumab (Humira, AbbVie) for sight-threatening non-infectious posterior uveitis.
Ranibizumab proves effective for DMO in NHS clinicsPatients treated for diabetic macular oedema with ranibizumab in the UK National Health Service (NHS) are getting benefits similar to those seen in clinical trials, according to a new study
Diabetic retinopathy and macular oedema increase in SpainDiabetic retinopathy and diabetic macular oedema are both increasing in Spain, especially among relatively young people, researchers said.
Latest concepts in steroid therapy for diabetic macular oedemaSteroids are an important second-line treatment for the treatment of diabetic macular oedema. While side effects remain a concern, modern formulations of intravitreal steroid allow the treatment to be tailored to the individual patient.
Outer retinal layer thickness predicts visual acuity in diabetic macular oedemaDiabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
Comparing anti-VEGFs for DMEIn a 1-year comparison of intravitreous aflibercept, bevacizumab and ranibizumab therapy for centre-involved DME, aflibercept was more effective at improving vision among patients who started treatment at lower levels of visual acuity.
Triamcinolone affects OCT reflectivity in DMEPatients who receive triamcinolone acetonide treatment for DME demonstrate changes in OCT reflectivity in their foveal cystoid spaces that are associated with a rebound in macular thickening and visual deterioration.